## Agenda Item 1

### Adoption of the Agenda

CX/RVDF 20/25/1

### Matters referred by CAC and other subsidiary bodies

CX/RVDF 20/25/2

### Matters of interest arising from FAO/WHO including JECFA88

CX/RVDF 20/25/3

### Report of the Joint FAO/WHO Expert Meeting on Carry-over in feed and transfer from feed to food of unavoidable and unintended residues of approved veterinary drugs

CX/RVDF 20/25/3-Add.1

### Matters of interest arising from the Joint FAO/IAEA Division of Nuclear Techniques in Food relevant to CCRVDF work

CX/RVDF 20/25/3-Add.2

### Report of the OIE activities, including the harmonization of technical requirements for registration of veterinary medicinal products (VICH)

CX/RVDF 20/25/4

### Draft MRL for flumethrin (honey) at Step 7

REP18/RVDF-App. IV CL 2020/17-RVDF

#### Comments at Step 6 (in reply to CL 2020/17-RVDF)

CX/RVDF 20/25/5

### Proposed draft MRLs for diflubenzuron (salmon - muscle plus skin in natural proportion); halquinol (in swine - muscle, skin plus fat, liver and kidney); ivermectin (sheep, pigs and goats – fat, kidney, liver and muscle) at Step 4

CL 2020/17-RVDF

#### Comments at Step 3 (in reply to CL 2020/17-RVDF)

CX/RVDF 20/25/6

### Proposed draft MRLs for zilpaterol hydrochloride (cattle fat, kidney, liver, muscle) (JECFA81 and JECFA85) retained Step 4

REP18/RVDF-App. III CX/RVDF 20/25/7 (See Explanatory Note)

---

Please note that there will be no distribution of working documents through the Codex mailing list (Codex-L). Only the invitation and the provisional agenda will be distributed to members and observers. All working documents, and any subsequent new documents not referenced on this Provisional Agenda, including any other information for delegates, will be published on the Codex website as they become available. Working documents will not be printed and delegates are kindly requested to bring with them to the meeting all documents which have been distributed as no printed copies will be made available at the session.

Website meeting page – [CCRVDF25](#)
<table>
<thead>
<tr>
<th>Item</th>
<th>Subject</th>
<th>Document</th>
</tr>
</thead>
<tbody>
<tr>
<td>7</td>
<td>Discussion paper on extrapolation of MRLs to one or more species (including a pilot on extrapolation on MRLs identified in Part D of the Priority List – REP18/RVDF, App. VI)</td>
<td>CX/RVDF 20/25/8</td>
</tr>
<tr>
<td>8</td>
<td>Discussion paper on the development of a harmonized definition for edible tissues of animal origin (including edible offal) (coordination between CCPR and CCRVDF)</td>
<td>CX/RVDF 20/25/9</td>
</tr>
<tr>
<td>9</td>
<td>Discussion paper on advantages and disadvantages of a parallel approach to compound evaluation</td>
<td>CX/RVDF 20/25/10</td>
</tr>
<tr>
<td>10</td>
<td>Database on countries’ needs for MRLs</td>
<td>CX/RVDF 20/25/11</td>
</tr>
<tr>
<td>11</td>
<td>Priority list of veterinary drugs requiring evaluation or re-evaluation by JECFA (replies to CL 2020/18-RVDF)</td>
<td>CX/RVDF 20/25/12 (See Explanatory Note)</td>
</tr>
<tr>
<td>12</td>
<td>Other business and future work</td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>Date and place of next session</td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>Adoption of the draft report</td>
<td></td>
</tr>
</tbody>
</table>

**NOTES TO THE PROVISIONAL AGENDA**

**Establishment of MRLs for veterinary drugs**

**Agenda Item 6.2:** Proposed draft MRLs for zilpaterol hydrochloride (cattle fat, kidney, liver, muscle) (JECFA81 and JECFA85) - CCRVDF24 agreed to retain these MRLs at Step 4 for further consideration at CCRVDF25 therefore no further comments are requested on this MRL. Document CX/RVDF 20/25/7 provides consolidated information of the outcomes of the JECFA81 and JECFA85 evaluations as well as the discussions at CCRVDF and CAC on this compound to facilitate discussion at CCRVDF25.

**Agenda Item 11:** Priority list of veterinary drugs requiring evaluation or re-evaluation by JECFA – The replies to CL 2020/18-RVDF as compiled in CX/RVDF 20/25/11 will be considered by the PWG on the Priority List which will provide a summary report for consideration by CCRVDF as contained in CRD02.

**All agenda items related to the establishment of MRLs for veterinary drugs:** Support document to the discussion on the MRLs and RMRs for residues of veterinary drugs is provided in RVDF25/INF01.